AuroMedics Pharma LLC recalls Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL)…
The stated reason: Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).
AuroMedics Pharma LLC began a drug recall on February 07, 2020 whose reported distribution included Ohio. FDA
What the record shows
FDA graded it Class III — use is not likely to cause adverse health consequences. Quantity affected: 4600 Vials. The recall is listed as terminated. FDA
Context
By the numbers
- Date of record: February 07, 2020 FDA
- Recall number: D-0853-2020 FDA
- Recalls in this action: 1 FDA
- Recalling firm: AuroMedics Pharma LLC FDA
- Product: Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or… FDA
- Reason for recall: Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative… FDA
Assembled mechanically from the source filing and The Lantern's own record database — no AI-written prose. Every figure above appears verbatim in the cited record, which is linked on this page. FDA
Sources
The source filing
| Recall number | D-0853-2020 |
|---|---|
| Recalls in this action | 1 |
| Recalling firm | AuroMedics Pharma LLC |
| Product | Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20. |
| Reason for recall | Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples). |
| Classification | Class III — use is not likely to cause adverse health consequences |
| Recall type | drug |
| Quantity | 4600 Vials |
| Status | Terminated |
| Voluntary or mandated | Voluntary: Firm initiated |
| Initiated | 20200207 |
| Reported | 20200226 |
| Distribution | Ohio, Louisiana, Mississippi |
| Firm location | East Windsor, NJ, United States |
Published by U.S. Food and Drug Administration (openFDA). This is the agency's public filing as The Lantern received it, shown with its fields named in plain English.